CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ 32,779	$ 135,817	$ (9,602)
Adjustments to reconcile net income ( loss) to net cash provided by (used in) operating activities:
Depreciation and amortization	69,103	6,984	3,085
Amortization of premium/discount on purchased securities	2,152	2,080	2,758
Write-down of inventory to net realizable value	1,235	1,309	2,175
Gain (loss) on disposal of property and equipment		(103)	(924)
Non-cash equity-based compensation expense	17,237	8,625	8,004
Non-cash loss on debt extinguishment	6,426
Amortization of debt discount and debt issuance costs	11,379	6,870
Gains on investments, net	(14)	(114)	(40)
Change in fair value of contingent consideration	4,271	(681)	1,074
Deferred income taxes	5,007	(153,159)
Changes in operating assets and liabilities:
Accounts receivable, net	(36,913)	3,588	(432)
Inventories	(5,237)	(1,360)	(1,040)
Receivable from collaboration	4,090	(4,239)	(15)
Prepaid and other current assets	4,034	2,331	2,817
Other long-term assets	9,209	1,964	(1,964)
Accounts payable and accrued expenses	7,876	10,694	(5,730)
Deferred revenues	(22,197)	(8,384)	(6,694)
Other long-term liabilities	(1,965)	(808)	(246)
Repayment of term loan attributable to original issue discount	(12,491)
Net cash provided by (used in) operating activities	95,981	11,414	(6,774)
Cash flows from investing activities:
Proceeds from sales or maturities of investments	208,966	223,568	106,030
Purchase of investments	(424,759)	(63,747)	(115,046)
Change in restricted cash	(195)	2,883	(2,823)
Capital expenditures, net of proceeds from sale of assets	(1,259)	(44)	1,338
Net cash (used in) investing activities	(899,041)	(432,942)	(13,935)
Cash flows from financing activities:
Proceeds from the issuance of common stock, net of underwriting discounts and other expenses	407,477
Long-term debt principal payments	(327,509)
Proceeds from issuance of convertible 2.5% notes		200,000
Proceeds from 2015 term loan	344,750
Proceeds from long-term debt	490,000	327,509
Payment of debt issuance costs	(10,004)	(7,760)
Proceeds from issuance of warrants		25,620
Purchase of convertible bond hedges		(39,760)
Payment of contingent consideration	(456)	(270)	(51)
Payment to former CBR shareholders	(7,195)
Proceeds from the exercise of stock options	15,406	8,499	1,277
Proceeds from the issuance of common stock under ESPP			176
Net cash provided by financing activities	912,469	513,838	1,402
Net increase (decrease) in cash and cash equivalents	109,409	92,310	(19,307)
Cash and cash equivalents at beginning of the period	119,296	26,986	46,293
Cash and cash equivalents at end of the period	228,705	119,296	26,986
Supplemental data of cash flow information:
Cash paid for taxes	2,373
Cash paid for interest	28,014	2,500
Non-cash investing activities:
Fair value of acquisition-related contingent consideration		205,000	13,700
Fair value of common stock issued in connection with the Lumara Health acquisition		111,964
Lumara Health
Adjustments to reconcile net income ( loss) to net cash provided by (used in) operating activities:
Change in fair value of contingent consideration	8,300	1,600
Cash flows from investing activities:
Acquisition of Lumara Health, net of acquired cash	562	(595,602)
CBR Acquisition Holdings Corp
Cash flows from investing activities:
Acquisition of CBR, net	(682,356)
MuGard
Adjustments to reconcile net income ( loss) to net cash provided by (used in) operating activities:
Change in fair value of contingent consideration	$ (4,000)	$ (2,300)
Cash flows from investing activities:
Acquisition of MuGard Rights and inventory			$ (3,434)